Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study

• Published in: Rheumatology (Oxford, England) Vol. 62; no. 4; pp. 1576 - 1585
• Main Authors: Barilaro, Giuseppe, Esteves, Alexandra, Della Rocca, Carlo, Perez-Isidro, Albert, Araujo, Olga, Pires da Rosa, Gilberto, Ruiz-Ortiz, Estibaliz, Tàssies Penella, Dolors, Viñas, Odette, Reverter, Joan Carles, Cervera, Ricard, Espinosa, Gerard
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 03.04.2023
• Subjects: Anticoagulants - therapeutic use; Antiphospholipid Syndrome - chemically induced; Antiphospholipid Syndrome - diagnosis; Antiphospholipid Syndrome - drug therapy; Female; Humans; Longitudinal Studies; Pregnancy; Retrospective Studies; Thrombosis - chemically induced; adjusted global APS score; APS; clinical recurrence; time spent within the therapeutic range
• ISSN: 1462-0324; 1462-0332
• DOI: 10.1093/rheumatology/keac485

Abstract Objective To assess the effect of the average adjusted global APS score (aGAPSS) over time on recurrence of clinical manifestations in APS patients through a retrospective longitudinal study. Material and methods The study included 200 patients with APS. The aGAPSS was calculated for each patient at baseline and on a yearly basis for either up to 6 years (minimum 3 years) or just before the clinical event in patients who experienced clinical recurrence. The mean score per patient was computed. In patients under vitamin K antagonists (VKA) the percentage of time spent within the therapeutic range (TTR) was calculated. Cox regression analysis was performed to determine the cut-off value of the aGAPSS with the strongest association with clinical recurrence. Results Higher average aGAPSS values were found in patients who experienced clinical recurrence in comparison to patients who did not [8.81 (95% CI 7.53, 10.08) vs 6.38 (95% CI 5.64, 7.12), P = 0.001], patients with thrombotic recurrence compared with patients with obstetric recurrence [9.48 (95% CI 8.14, 10.82) vs 4.25 (95% CI 0.85, 7.65), P = 0.006] and patients with arterial thrombosis compared with patients with venous thrombosis [10.66 (S.D. 5.48) vs 6.63 (S.D. 4.42), P = 0.01]. aGAPSS values >13 points were associated with the highest risk of recurrence in multivariate analysis [HR = 3.25 (95% CI 1.93, 5.45), P < 0.0001]. TTR was not statistically different between patients who had thrombosis recurrence and patients who had not. Conclusions Our data support the role of periodic (annual) monitoring of the aGAPSS score in predicting clinical recurrence in patients with APS.